25,708 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,708 shares of the company's stock, valued at approximately $448,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the fourth quarter worth about $53,000. Quarry LP bought a new stake in Travere Therapeutics in the 3rd quarter valued at approximately $105,000. Victory Capital Management Inc. acquired a new position in Travere Therapeutics during the 4th quarter worth approximately $182,000. Baader Bank Aktiengesellschaft bought a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $192,000. Finally, Entropy Technologies LP acquired a new stake in shares of Travere Therapeutics in the fourth quarter valued at approximately $214,000.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. HC Wainwright raised their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, January 15th. Evercore ISI lifted their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a research report on Friday, February 21st. Finally, Citigroup boosted their price target on Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.62.

Remove Ads

Insider Buying and Selling

In related news, SVP William E. Rote sold 2,437 shares of the company's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the transaction, the senior vice president now directly owns 83,170 shares in the company, valued at approximately $1,618,488.20. This represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Sandra Calvin sold 3,348 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $67,361.76. Following the transaction, the chief accounting officer now directly owns 63,654 shares in the company, valued at approximately $1,280,718.48. This represents a 5.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 191,335 shares of company stock valued at $4,194,712. Insiders own 3.75% of the company's stock.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded down $0.69 during mid-day trading on Friday, reaching $19.68. 1,138,538 shares of the company were exchanged, compared to its average volume of 1,477,454. The stock has a market capitalization of $1.75 billion, a P/E ratio of -4.80 and a beta of 0.75. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The company's 50-day simple moving average is $20.76 and its 200-day simple moving average is $18.49. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. As a group, research analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.